Oracle Corp SEC Filings

Greif, Inc. (GEF) filed a Form 144 disclosing that an insider plans to sell up to 19,248 Class A shares through Fidelity Brokerage Services on or about 01 July 2025. The block carries an aggregate market value of $1.35 million and represents approximately 0.07 % of the 26.13 million Class A shares outstanding.

The filing also lists a prior disposition: on 09 June 2025 the same individual, named as Ole Rosgaard, sold 30,000 Class A shares for gross proceeds of $1.97 million. Taken together, recent and proposed sales total 49,248 shares, or roughly 0.19 % of the current float.

The shares to be sold were acquired on 16 January 2024 via restricted-stock vesting and are being sold for the insider’s own account. No operational, earnings or strategic information is included; the document strictly serves as notice under Rule 144 and contains the standard representation that the seller is not in possession of undisclosed material adverse information.

For investors, the key takeaway is the continued insider selling activity, which, while small relative to total shares outstanding, may be monitored as a gauge of insider sentiment toward Greif’s equity.

Cellectar Biosciences (Nasdaq: CLRB) filed Amendment No. 1 to its Form S-1 on 30 June 2025, seeking to register a follow-on public offering of up to 755,667 Class A Units or, at investors’ election, an equal number of Class B Units. Each Class A Unit contains one share of common stock and one five-year common warrant; each Class B Unit substitutes the share with a pre-funded warrant priced at $0.00001 to mitigate ownership-limit issues (4.99% or 9.99% caps).

The filing covers up to 1,556,674 shares issuable upon exercise of pre-funded, common and representative warrants, plus an underwriters’ 45-day over-allotment option for up to 113,350 additional shares and/or warrants. Representative warrants equal to 6% of units sold will also be issued. The assumed public offering price is $7.94, the last closing price on 25 June 2025; final pricing will be set through negotiation with lead underwriter Ladenburg Thalmann.

On 24 June 2025 the company completed a 1-for-30 reverse stock split, leaving authorized share count and par value unchanged. Following the split, Cellectar remains a non-accelerated filer and smaller reporting company. The S-1 reiterates that investing in the securities involves a “high degree of risk,” directing readers to a dedicated Risk Factors section starting on page 17. Proceeds, net of underwriting fees and expenses, are not quantified here and will depend on final pricing and warrant exercise, while the company reserves the right to delay effectiveness until it files a further amendment.

Oracle CEO Safra Catz filed Form 144 indicating a proposed sale of 1,260,508 shares of common stock with an aggregate market value of $267.2 million. The shares were acquired through stock options exercise on June 27, 2025, and are planned to be sold through Fidelity Brokerage Services on the NYSE.

The filing reveals significant recent selling activity by Catz in the past week:

• June 20: 2,284,371 shares for $474.2M
• June 23: 1,410,547 shares for $289.8M
• June 25: 1,873,791 shares for $397.8M
• June 26: 1,865,701 shares for $396.9M

The sales are being executed under a 10b5-1 trading plan adopted on September 25, 2024. The shares are being sold from the Harbor Island Joint Rev Trust. Oracle's total shares outstanding are approximately 2.81 billion.

Oracle (NYSE:ORCL) filed a Form 4 disclosing CEO Safra Catz’s cashless option exercises and same-day sales on 25-26 Jun 2025.

• Options exercised: 3.74 M shares at $51.13; 5 M new performance-based options granted 24 Jun 2025.
• Shares sold: 3.74 M shares at weighted-average prices of $210.64-$215.44, realising ≈$793 M.
• Post-transaction ownership: 1,118,592 directly-held shares (unchanged) plus 1.26 M unexercised options.

The sizeable monetisation, though executed under a Rule 10b5-1 plan, may influence investor sentiment and raises governance questions about pay design.

Larry Ellison, Oracle's Executive Chairman, Chief Technology Officer, and 10% owner, received a significant stock option grant on June 24, 2025. The Form 4 filing discloses the acquisition of 5,000,000 stock options with the following key details:

• Exercise price set at $51.13 per share
• Options become exercisable on June 24, 2025
• Expiration date is July 20, 2025
• Represents 2/7 of shares from a performance-based option that vested upon Compensation Committee certification

This transaction indicates a significant performance-based compensation award for Ellison, who holds multiple leadership roles at Oracle. The short exercise window (approximately one month) and the performance-based vesting conditions suggest this is part of a structured executive compensation plan tied to specific company goals.

Oracle CEO Safra Catz Files Form 144 for Significant Stock Sale

Oracle CEO Safra Catz has filed a Form 144 notice indicating plans to sell 1,865,701 shares of Oracle common stock with an aggregate market value of $396.85 million. The shares were acquired through stock options exercise on June 26, 2025, and are planned to be sold via Fidelity Brokerage Services on the NYSE.

Notable recent trading activity by Catz in the past 3 months includes:

• June 20, 2025: Sold 2,284,371 shares for $474.22 million
• June 23, 2025: Sold 1,410,547 shares for $289.79 million
• June 25, 2025: Sold 1,873,791 shares for $397.78 million

The shares are being sold from the Harbor Island Joint Rev Trust. The sale follows a Rule 10b5-1 trading plan adopted on September 25, 2024. Oracle's total shares outstanding stand at 2.81 billion.

Oracle Corp Vice Chairman and Director Jeffrey Henley reported a significant insider transaction on June 23, 2025, involving the disposition of 147,000 shares of Common Stock through a gift transaction (Transaction Code: G) at $0 per share.

Following the transaction, Henley maintains substantial indirect ownership positions through various trusts:

• 950,576 shares held through Trust
• 145,114 shares held through GRAT (Grantor Retained Annuity Trust)
• 362,029 shares held through Henley Community Property Trust

The Form 4 filing was submitted by Aimee Weast, acting as Attorney in Fact for Henley under a Power of Attorney filed on March 20, 2019. This gift transaction suggests estate planning or charitable giving activities by the insider while maintaining significant beneficial ownership in Oracle.

Oracle Corp Form 144 filing reveals CEO Safra Catz's planned sale of 1,873,791 shares of common stock with an aggregate market value of $397.8 million through Fidelity Brokerage Services. The transaction is scheduled for June 25, 2025, on the NYSE.

Key transaction details:

• Shares were acquired through stock options exercise on June 25, 2025
• Payment was made in cash
• Total outstanding shares: 2.81 billion

Notable recent trading activity by Catz in the past 3 months:

• June 20, 2025: Sold 2,284,371 shares for $474.2 million
• June 23, 2025: Sold 1,410,547 shares for $289.8 million

This Form 144 represents a significant insider transaction, with Catz selling approximately $1.16 billion worth of Oracle stock within a one-week period.

Oracle CEO Safra Catz reported significant insider trading activity through a pre-planned Rule 10b5-1 trading plan. On June 20-23, 2025, Catz exercised stock options for 3,694,918 shares at $51.13 per share and subsequently sold them in multiple transactions.

The transactions included:

• Exercise of 2,284,371 shares on June 20, followed by sales at prices ranging from $204.64 to $213.33
• Exercise of 1,410,547 shares on June 23, followed by sales at prices ranging from $202.63 to $207.23

Following these transactions, Catz's direct ownership stands at 1,118,592 shares. The stock options were part of a performance-based compensation package, with each exercise representing 1/7 of the vested options. The sales were executed pursuant to a Rule 10b5-1 plan established on September 25, 2024, demonstrating pre-planned, compliant insider selling activity.